Relay Therapeutics Stock - Weekly review and sector context after muted news flow
19.06.2026 - 22:11:45 | ad-hoc-news.de
Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 20:06 UTC. Details in the imprint.
Relay Therapeutics (US76034L1026) is ending the week for its stock with no new company-specific filings or major headlines from primary newswires. Investors are therefore looking at the recent share performance, the broader biotech sector backdrop and the company’s existing guidance from prior quarters.
All news and key data on Relay Therapeutics
Follow past disclosures and price data for Relay Therapeutics stock to see how the story has developed over recent quarters.
What this quiet week shows
Relay Therapeutics has not published a new press release, SEC filing or guidance update over the past 24 hours, based on checks of its investor relations page and US filings. The most recent detailed communication remains its prior quarterly report and pipeline update from earlier in 2026.
On the market side, the latest available closing quote for Relay Therapeutics shares on Nasdaq was $15.88 on 06/18/2026, corresponding to a gain of 2.1% on that day according to MarketBeat data. MarketBeat quote overview for Relay Therapeutics Extended trading after the close showed activity around $16.21 on the same date, signaling continued interest from investors outside regular hours.
How the stock compares in biotech
The company trades in a volatile part of the market, with many early and mid-stage biotechnology names on Nasdaq experiencing sharp swings as trial readouts and regulatory decisions arrive. Relay Therapeutics is no exception, with its valuation sensitive to data from its targeted oncology programs.
Compared with larger diversified biotech and pharmaceutical groups, smaller precision oncology developers like Relay Therapeutics typically show higher beta and more pronounced reactions to news. That dynamic has been visible after past data releases, when RLAY shares have often moved more strongly than broad biotech indices.
The product engine behind Relay Therapeutics
Relay Therapeutics builds its business on a structure-based drug discovery platform aimed at precision oncology. A key clinical asset is the FGFR2 selective inhibitor RLY-4008, which the company is developing for certain solid tumors with FGFR2 alterations, alongside other small-molecule candidates in its pipeline.
Where the stock trades today
The shares of Relay Therapeutics (US76034L1026) last closed on Nasdaq at $15.88 on 06/18/2026 at 04:00 PM Eastern Time, with extended trading indications around $16.21 later that evening in US dollars.
Key facts on Relay Therapeutics stock
- Company: Relay Therapeutics, Inc.
- ISIN: US76034L1026
- WKN: A2PP75
- Ticker: RLAY
- Venue: Nasdaq
- Price (as of 06/18/2026, 16:00 ET): 15.88 USD
- Market cap: 2,08 billion USD (as of 06/18/2026)
- Sector / Industry: Health Care / Biotechnology
- Index membership: not a member of the S&P 500 or Nasdaq-100
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
